Bullous Pemphigoid Disease: A Comprehensive Review

Introduction

Bullous pemphigoid (BP) is a chronic, autoimmune subepidermal blistering disorder that primarily affects older adults. Characterised by tense blisters and pruritus, Bullous pemphigoid is a prototypical example of an autoimmune bullous disease, with significant implications for morbidity and quality of life. Over the past several decades, understanding of the disease’s pathogenesis, diagnosis, and management has evolved considerably, driven by advances in immunology and dermatopathology.

Historical Background

The first descriptions of Bullous pemphigoid date back to the early twentieth century, though it was not until the 1950s that it was distinguished from pemphigus vulgaris and other blistering diseases. The term “pemphigoid” was coined to indicate conditions resembling pemphigus but with key clinical and histological differences. Immunopathological techniques developed in the 1960s, particularly direct immunofluorescence, enabled the definitive characterisation of Bullous pemphigoid as an autoimmune disorder, marking a turning point in its understanding and diagnosis.

Epidemiology

BP is regarded as the most common autoimmune blistering disease, particularly in the elderly. Its incidence is estimated at 2–14 cases per million per year in Europe and North America, with higher rates observed in populations with increased life expectancy. In India and other Asian countries, prevalence is lower but may be rising due to improved recognition and ageing populations. The disease typically presents in individuals over the age of 60, with a slight predominance in females. There is no strong racial predilection, though regional variations exist. Mortality rates are higher in BP patients compared to age-matched controls, primarily due to disease complications and comorbidities.

Aetiology and Risk Factors

The precise cause of Bullous pemphigoid is multifactorial, involving a complex interplay of genetic predisposition, environmental factors, and immunological triggers.

Genetic Factors

Although Bullous pemphigoid is not inherited in a classic Mendelian fashion, certain genetic markers increase susceptibility. Associations with human leukocyte antigen (HLA) alleles, such as HLA-DQB1*0301, have been reported. These genetic factors are thought to influence antigen presentation and the likelihood of autoimmune responses against basement membrane components. Family clustering is rare, but cases of familial Bullous pemphigoid have been documented, suggesting a potential, albeit limited, hereditary component.

Environmental Triggers

Several environmental factors have been implicated as triggers for BP. These include:

• Drugs: Certain medications, such as loop diuretics (e.g., furosemide), antibiotics (e.g., penicillamine), antipsychotics, and DPP-4 inhibitors (used in diabetes), have been associated with BP onset.
• Physical factors: Trauma, burns, radiotherapy, and ultraviolet exposure can precipitate lesions in predisposed individuals.
• Neurological diseases: There is a well-documented association between BP and neurological disorders such as dementia, Parkinson’s disease, and stroke. Shared antigens between the skin and nervous system may contribute to this link.

Immunological Factors

Autoimmunity is central to BP pathogenesis. The breakdown of immune tolerance to components of the dermal-epidermal junction, possibly triggered by infections, medications, or age-related immune dysregulation, results in the production of pathogenic autoantibodies.

Pathophysiology

BP is a prototypical antibody-mediated autoimmune disease. The immune response is directed against specific proteins in the basement membrane zone (BMZ) of the skin, principally BP180 (also known as type XVII collagen) and BP230, which are components of hemidesmosomes that anchor basal keratinocytes to the basement membrane.

Autoantibodies and Target Antigens

The pathogenic autoantibodies in BP are predominantly of the IgG class, although IgE autoantibodies have also been detected and may contribute to disease activity.

• BP180 (collagen XVII): A transmembrane protein with an extracellular domain (NC16A) that is the primary target for autoantibodies. Binding of autoantibodies to BP180 leads to complement activation and recruitment of inflammatory cells.
• BP230: An intracellular plakin family protein involved in cytoskeletal attachment; autoantibodies to BP230 are less common but may contribute to disease pathogenesis.

Immune Response and Inflammation

Autoantibody binding to BMZ antigens initiates a cascade of immunological events:

1. Activation of the classical complement pathway, resulting in the generation of C3a and C5a, potent chemoattractants for neutrophils and eosinophils.
2. Infiltration of the dermis by inflammatory cells, especially eosinophils, neutrophils, and lymphocytes.
3. Release of proteolytic enzymes, reactive oxygen species, and cytokines, leading to degradation of BMZ components and subepidermal blister formation.

The role of Th2-type immune responses and cytokines such as interleukin-4, interleukin-5, and eotaxin in promoting eosinophilic infiltration is increasingly recognised.

Clinical Features

BP presents with a range of cutaneous manifestations, which may vary in severity and distribution. Early recognition is crucial for optimal management.

Prodromal and Non-bullous Phase

The initial phase may be characterised by nonspecific symptoms such as pruritus, urticarial or eczematous plaques, and erythema, often preceding blister formation by weeks or months. These lesions can be mistaken for other dermatological conditions, delaying diagnosis.

Bullous Phase

The hallmark of BP is the development of tense, fluid-filled blisters (bullae) on normal or erythematous skin. Key features include:

• Tense, dome-shaped bullae, typically 1–5 cm in diameter, filled with clear or haemorrhagic fluid
• Common sites: flexural aspects of the limbs, lower abdomen, groin, and axillae; mucous membrane involvement is less frequent than in pemphigus vulgaris
• Itching is often intense and may be the predominant symptom
• Blisters may rupture, resulting in erosions, crusting, and secondary infections

Variants and Differential Diagnosis

Several clinical variants of BP are recognised, including:

• Localised BP: limited to a particular body region
• Vesicular BP: presents with smaller blisters resembling dermatitis herpetiformis
• Vegetating BP: rare form with hypertrophic lesions
• Childhood BP: rare, with similar features but better prognosis

The differential diagnosis includes pemphigus vulgaris, dermatitis herpetiformis, linear IgA disease, bullous drug eruptions, epidermolysis bullosa acquisita, and other blistering disorders. Distinguishing these entities relies on clinical, histopathological, and immunopathological findings.

Diagnosis

The diagnosis of BP is based on a combination of clinical assessment, histopathology, and immunopathological investigations.

Clinical Evaluation

A thorough history and physical examination are essential. Important aspects include:

• Age and onset of symptoms
• Nature, distribution, and evolution of skin lesions
• Presence of pruritus and mucosal involvement
• Potential triggers, such as recent medication changes

Laboratory Investigations

Routine laboratory tests may show eosinophilia and elevated inflammatory markers but are non-specific.

Histopathology

A skin biopsy of an early blister reveals:

• Subepidermal blister with an inflammatory infiltrate, predominantly eosinophils and neutrophils, in the upper dermis
• Absence of acantholysis (differentiating BP from pemphigus vulgaris)

Direct Immunofluorescence (DIF)

DIF is the gold standard for BP diagnosis. A perilesional skin biopsy typically shows:

• Linear deposition of IgG and complement component C3 along the basement membrane zone

This finding distinguishes BP from other blistering diseases.

Indirect Immunofluorescence (IIF) and ELISA

Serological testing for circulating autoantibodies may be performed:

• IIF detects circulating IgG autoantibodies binding to the BMZ of salt-split skin substrate
• ELISA assays for anti-BP180 and anti-BP230 autoantibodies provide quantitative data, useful for diagnosis and monitoring disease activity

Treatment Modalities

The main objectives in BP management are to control symptoms, promote healing, prevent complications, and minimise treatment-related adverse effects. Therapeutic approaches are individualised based on disease severity, patient comorbidities, and risk factors.

Pharmacological Therapies

Topical Corticosteroids

High-potency topical corticosteroids (e.g., clobetasol propionate) are effective, especially in localised or moderate disease. They reduce inflammation and promote resolution of lesions. Topical therapy may be preferred in elderly patients to minimise systemic side effects.

Systemic Corticosteroids

Systemic corticosteroids (e.g., prednisolone) remain the mainstay for severe or widespread BP. Initial doses typically range from 0.5–1 mg/kg/day, with gradual tapering as lesions resolve. Long-term use is associated with significant adverse effects, particularly in the elderly (osteoporosis, diabetes, infections, hypertension).

Immunosuppressive Agents

Steroid-sparing immunosuppressants are used to reduce corticosteroid dependency and toxicity. Common agents include:

• Azathioprine
• Mycophenolate mofetil
• Methotrexate
• Cyclophosphamide

Choice of agent depends on patient factors, efficacy, and side-effect profile.

Other Pharmacological Options

• Tetracyclines and Nicotinamide: These agents have anti-inflammatory properties and may be useful in mild BP or as adjuncts.
• Dapsone: Particularly effective in neutrophil-predominant variants.
• Rituximab: Anti-CD20 monoclonal antibody, increasingly used in refractory or relapsing BP, with promising results in reducing disease activity.
• Intravenous Immunoglobulin (IVIG): Used in severe, treatment-resistant cases.

Non-pharmacological Management

Supportive care is crucial, particularly in elderly or debilitated patients. This includes:

• Wound care and prevention of secondary infection
• Management of pruritus with antihistamines
• Nutrition and hydration support
• Patient and caregiver education

Emerging and Experimental Treatments

Recent years have seen the development of novel therapies targeting specific immune pathways. These include:

• Biologics targeting IL-4, IL-5, or eosinophil activity
• Janus kinase (JAK) inhibitors
• FcRn antagonists to reduce circulating IgG levels

While still under investigation, these treatments hold promise for patients with refractory BP or contraindications to conventional therapies.

Prognosis and Complications

BP is a potentially life-threatening disease, particularly in elderly patients with comorbidities. However, with appropriate management, remission can be achieved in most cases.

Disease Course and Outcomes

The natural history of BP is variable. Untreated, the disease may persist for months to years, with spontaneous remissions and relapses. With treatment, most patients achieve disease control within weeks to months, though relapses are common, particularly during corticosteroid tapering.

Complications

• Infections: Secondary bacterial infection of erosions is common and may be life-threatening.
• Adverse effects of treatment: Long-term corticosteroid and immunosuppressant use increases the risk of osteoporosis, diabetes, hypertension, and opportunistic infections.
• Chronic wounds and scarring: Persistent erosions may lead to scarring, particularly in mucosal variants.
• Quality of life: Pruritus, pain, and the psychosocial impact of chronic skin disease can be considerable.

Mortality

Mortality rates in BP are higher than in the general population, mainly due to infections, complications of immunosuppression, and underlying comorbidities. Early diagnosis and a multidisciplinary approach are essential to improving outcomes.

Nursing Care of Patient with Bullous Pemphigoid

Nursing Interventions

Blister Management:

1. Protect intact blisters to prevent rupture and secondary infection.
2. Cover ruptured blisters with sterile, non-adherent dressings.
3. Change dressings regularly, using aseptic technique.

Skin Care:

1. Maintain skin hygiene with gentle cleansing and patting dry.
2. Avoid harsh soaps, friction, and adhesive tapes on affected areas.
3. Apply prescribed topical steroids or immunosuppressive agents as directed.

Infection Prevention:

1. Monitor for signs of local and systemic infection.
2. Educate patient and caregivers about hand hygiene and wound care.
3. Administer antibiotics if prescribed.

Pain Management:

1. Administer analgesics as prescribed.
2. Use non-pharmacological methods such as relaxation techniques and cold compresses when appropriate.

Nutrition and Hydration:

1. Encourage a balanced diet rich in proteins, vitamins, and minerals to promote skin healing.
2. Monitor and support adequate fluid intake.
3. Assist with feeding if oral blisters cause difficulty swallowing.

Mobility Support:

1. Assist with movement to avoid trauma to fragile skin.
2. Provide mobility aids as needed.

Patient and Family Education

1. Explain the nature of Bullous Pemphigoid, its chronicity, and the importance of ongoing care.
2. Educate about medication adherence, including possible side effects of steroids and immunosuppressants.
3. Teach wound care techniques, dressing changes, and infection signs.
4. Advise on skin protection strategies, such as wearing loose-fitting clothes and avoiding trauma.
5. Discuss psychosocial support options, including counselling and support groups.

Complications and Prevention

• Secondary Infection: Promptly address any signs of infection and maintain strict aseptic technique.
• Steroid Side Effects: Monitor for hypertension, hyperglycaemia, osteoporosis, and other complications related to long-term steroid use.
• Impaired Mobility: Prevent falls by ensuring a safe environment and assisting with movement.
• Emotional Well-being: Encourage open communication and provide resources for psychological support.

REFERENCES

1. American Osteopathic College of Dermatology. Bullous Pemphigoid. https://www.aocd.org/page/BullousPemphigoid.
2. Culton DA, Liu Z, Diaz LA. Bullous Pemphigoid. In: Kang S, Amagai M, Bruckner AL, et al., eds. Fitzpatrick’s Dermatology. 9th Edition. McGraw Hill; 2019.
3. Huang L, Liu Y, Li H, et al. Bullous Pemphigoid and Diabetes medications: A disproportionality analysis based on the FDA Adverse Event Reporting System. https://ncbi.nlm.nih.gov/pmc/articles/PMC8040401/. Int J Med Sci. 2021;18 (9):1946-1952.
4. Joly P, Benichou J, Lok C, et al. Prediction of survival for patients with bullous pemphigoid: a prospective study. https://pubmed.ncbi.nlm.nih.gov/15967914/. Arch Dermatol. 2005;141(6): 691-698. .
5. Kirtschig G, Middleton P, Bennett C, et al. Interventions for bullous pemphigoid. https://pubmed.ncbi.nlm.nih.gov/20927731/. Cochrane Database Syst Rev. 2010;2010(10): CD002292.
6. Health Education & Content Services. Bullous pemphigoid. Mayo Clinic; 2024.
7. Kridin K, Ludwig RJ. The Growing Incidence of Bullous Pemphigoid: Overview and Potential Explanations. https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC6109638/. Front Med (Lausanne). 2018;5:220.
8. Shinkai K, Fox LP. Bullous Pemphigoid. In: Papadakis MA, McPhee SJ, Rabow MW, et al., eds. Current Medical Diagnosis & Treatment 2022. McGraw Hill; 2022.
9. Usatine RP, Morgan C. Bullous Pemphigoid. In: Usatine RP, Smith MA, Mayeaux, Jr. EJ, et al., eds. The Color Atlas and Synopsis of Family Medicine. 3rd Edition. McGraw Hill; 2019.
10. Yancey KB, Chong BF, Lawley TJ. Immunologically Mediated Skin Diseases. In: Loscalzo J, Fauci A, Kasper D, et al., eds. Harrison’s Principles of Internal Medicine. 21st Edition. McGraw Hill; 2021.

Stories are the threads that bind us; through them, we understand each other, grow, and heal.

JOHN NOORD

Connect with “Nurses Lab Editorial Team”

I hope you found this information helpful. Do you have any questions or comments? Kindly write in comments section. Subscribe the Blog with your email so you can stay updated on upcoming events and the latest articles.